CoChat

Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos

Open access
Babalola, O E, Bode, C O, Ajayi, A A, Alakaloko, F M, Akase, I E, Otrofanowei, E, Salu, O B, Adeyemo, W L, Ademuyiwa, A O, Omilabu, S · 2022 · QJM: An International Journal of Medicine

Published version of a preprint

Cited by 89

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Summary: Introduction: In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS—CoV-2 viral replication, but questions remained as to in-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. Methods: We conducted a translational proof of concept randomized, double blind placebo controlled, dose response and parallel group study of IV efficacy in RT—polymerase chain reaction proven COVID 19 positive patients. Sixty-two patients were randomized to three treatment groups. (A) IV 6 mg regime, (B) IV 12 mg regime (given Q84 h for 2 weeks) (C, control) Lopinavir/Ritonavir. All groups plus standard of Care. Results: The Days to COVID negativity (DTN) was significantly and dose dependently reduced by IV (P = 0.0066). The DTN for Control were, = 9.1+/–5.2, for A 6.0 +/– 2.9 and for B 4.6 +/–3.2. Two way repeated measures ANOVA of ranked COVID 19 +/– scores at 0, 84, 168 and252h showed a significant IV treatment effect (P = 0.035) and time effect (P < 0.0001). IV also tended to increase SPO2% compared to controls, P = 0.073, 95% CI—0.39 to 2.59 and increased platelet count compared to C (P = 0.037) 95%CI 5.55—162.55 × 103/ml. The platelet count increase was inversely correlated to DTN (r = –0.52, P = 0.005). No SAE was reported. Conclusions: 12mg IV regime given twice a week may have superior efficacy over 6mg IV given twice a week, and certainly over the non IV arm of the study. IV should be considered for use in clinical management of SARS-COV2, and may find applications in prophylaxis in high risk areas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/qjmed/hcab035

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 18

  1. Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 · DOI · Paper page
  2. Cucinotta, 2020, WHO Declares COVID-19 a pandemic, Acta Bio Medica Atenei Parm, 91, 157
  3. Khullar, 2020, COVID-19 and the financial health of US hospitals, JAMA, 323, 2127, 10.1001/jama.2020.6269 · DOI · Paper page
  4. Heidary, 2020, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot (Tokyo), 73, 593, 10.1038/s41429-020-0336-z · DOI · Paper page
  5. Abiose, 1993, Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis, Lancet, 341, 130, 10.1016/0140-6736(93)90002-X · doi:10.1016/0140-6736(93)90002-x
  6. Yang, 2020, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res, 177, 104760, 10.1016/j.antiviral.2020.104760 · DOI · Paper page
  7. Schmith, 2020, The approved dose of Ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther, 108, 762, 10.1002/cpt.1889 · DOI · Paper page
  8. Arshad, 2020, Prioritisation of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther, 10.1002/cpt.1909 · DOI
  9. Muñoz, 2018, Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg Tablet in healthy adult volunteers, PLoS Negl Trop Dis, 12, e0006020, 10.1371/journal.pntd.0006020 · DOI
  10. Zhang, 2008, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, 57, 524, 10.1007/s00011-008-8007-8 · DOI · Paper page
  11. Nandini, 2020, Interpreting diagnostic tests for SARS-CoV-2 Au, JAMA
  12. Ahmed, 2020, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
  13. Liao, 2020, Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study, Lancet Haematol, 7, e671, 10.1016/S2352-3026(20)30217-9 · DOI · Paper page
  14. Rajter, 2020, Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON Study, Chest, 159, 85, 10.1016/j.chest.2020.10.009 · DOI · Paper page
  15. DiNicolantonio, 2020, Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart, 7, e001350, 10.1136/openhrt-2020-001350 · DOI
  16. Hussman, 2020, Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention, Front Pharmacol, 11, 10.3389/fphar.2020.01169 · DOI · Paper page
  17. Mojtabavi, 2020, Interleukin-6 and severe COVID-19: a systematic review and meta-analysis, Eur Cytokine Netw, 31, 44, 10.1684/ecn.2020.0448 · DOI
  18. Luo, 2020, Signaling to control cytokine release syndrome in COVID-19, Trends Pharmacol Sci, 41, 531, 10.1016/j.tips.2020.06.007 · DOI · Paper page

Cited by

See all 89

Metadata

Authors
Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., & Omilabu, S.
Venue
QJM: An International Journal of Medicine
Published
2021-02-18
Volume
114
Issue
11
Pages
780-788
ISSN
  • 0033-5622 (ISSN-L)
  • 1460-2725
  • 1460-2393
OpenAlex
W3129242298
Cited by
89
References
6
FWCI
6.07
Type
journal article
Language
en
Open access
bronze
Funders
The Central Bank of Nigeria Health Sector Research and Development Intervention Scheme

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. https://app.cochat.ai/papers/10.1093/qjmed/hcab035
The paper
Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., & Omilabu, S. (2022). Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. QJM: An International Journal of Medicine. https://doi.org/10.1093/qjmed/hcab035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.